Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 3/2011

01-06-2011 | Case Report

Nephrotic syndrome developing during induction chemotherapy for childhood acute lymphoblastic leukemia

Authors: Chanel Prestidge, Shahrad Rod Rassekh, Douglas G. Matsell

Published in: Clinical and Experimental Nephrology | Issue 3/2011

Login to get access

Abstract

This report is the first to document minimal change nephrotic syndrome occurring during induction chemotherapy for childhood acute lymphoblastic leukemia (ALL). This occurrence lends further support to the theory of immune cell dysregulation being central to the pathogenesis of nephrotic syndrome in ALL, rather than alternative postulations that this association is due to an increased risk of malignancy secondary to prior immunosuppressive treatment for nephrotic syndrome.
Literature
1.
Papper S. Nephrotic syndrome and neoplasm. The findings to date, with practical implications. Postgrad Med. 1984;76(147–8):53–8.
2.
Dabbs DJ, Striker LM, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. Am J Med. 1986;80:63–70.CrossRef
3.
Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int. 1999;56:355–77.CrossRef
4.
Sinha R, AlAbbas A, Dionne JM, Hurley RM. Simultaneous occurrence of atypical hemolytic uremic syndrome and acute lymphoblastic leukemia: a case report and literature review. Pediatr Nephrol. 2008;23:835–9.CrossRef
5.
Lee JC, Yamauchi H, Hopper J Jr. The association of cancer and the nephrotic syndrome. Ann Intern Med. 1966;64:41–51.CrossRef
6.
Da’as N, Polliack A, Cohen Y, Amir G, Darmon D, Kleinman Y, et al. Kidney involvement and renal manifestations in non-Hodgkin’s lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol. 2001;67:158–64.CrossRef
7.
Bhatia M, Kher K, Minniti CP. Acute lymphoblastic leukemia in a child with nephrotic syndrome. Pediatr Nephrol. 2004;19:1290–3.CrossRef
8.
Kuis W, de Kraker J, Kuijten RH, Donckerwolcke RA, Voute PA. Acute lymphoblastic leukaemia after treatment of nephrotic syndrome with immunosuppressive drugs. Helv Paediatr Acta. 1976;31:91–5.PubMed
9.
Mackie FE, Roy LP, Stevens M. Onset of leukaemia after levamisole treatment for nephrotic syndrome. Pediatr Nephrol. 1994;8:527–8.CrossRef
10.
Muller W, Brandis M. Acute leukemia after cytotoxic treatment for nonmalignant disease in childhood. Eur J Pediatr. 1981;136:105–8.CrossRef
11.
Perard L, Thomas X, Jaumain H, Theuil G, Bret M, Coronel B, et al. T-cell lineage acute lymphoblastic leukemia with chromosome 5 abnormality in a patient with Crohn’s disease and lipoid nephrosis. Ann Hematol. 2000;79:222–5.CrossRef
12.
Rajpoot D, Tejani A, Rao S, Miller S. Focal segmental glomerulosclerosis in a child with acute lymphoblastic leukemia. Child Nephrol Urol. 1990;10:231–3.PubMed
13.
Sathiapalan RK, Velez MC, McWhorter ME, Irwin K, Correa H, Baliga R, et al. Focal segmental glomerulosclerosis in children with acute lymphocytic leukemia: case reports and review of literature. J Pediatr Hematol Oncol. 1998;20:482–5.CrossRef
14.
Fiser RT, Arnold WC, Charlton RK, Steele RW, Childress SH, Shirkey B. T-lymphocyte subsets in nephrotic syndrome. Kidney Int. 1991;40:913–6.CrossRef
15.
Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2:556–60.CrossRef
16.
Garin EH. Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol. 2000;14:872–8.CrossRef
17.
Bakker WW, van Luijk WH. Do circulating factors play a role in the pathogenesis of minimal change nephrotic syndrome? Pediatr Nephrol. 1989;3:341–9.CrossRef
18.
Gonzalez E, Neuhaus T, Kemper MJ, Girardin E. Proteomic analysis of mononuclear cells of patients with minimal-change nephrotic syndrome of childhood. Nephrol Dial Transplant. 2009;24:149–55.CrossRef
19.
Sahali D, Pawlak A, Valanciute A, Grimbert P, Lang P, Remy P, et al. A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol. 2002;13:1238–47.PubMed
20.
Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993;14:196–204.CrossRef
21.
Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica. 2007;92:139–40.CrossRef
22.
Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J. 2002;4:1006–8.PubMed
23.
Sahali D, Pawlak A, Le Gouvello S, Lang P, Valanciute A, Remy P, et al. Transcriptional and post-transcriptional alterations of IkappaBalpha in active minimal-change nephrotic syndrome. J Am Soc Nephrol. 2001;12:1648–58.PubMed
24.
Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin’s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005;65:264–76.PubMed
25.
Aggarwal N, Batwara R, McCarthy ET, Sharma R, Sharma M, Savin VJ. Serum permeability activity in steroid-resistant minimal change nephrotic syndrome is abolished by treatment of Hodgkin disease. Am J Kidney Dis. 2007;50:826–9.CrossRef
Metadata
Title
Nephrotic syndrome developing during induction chemotherapy for childhood acute lymphoblastic leukemia
Authors
Chanel Prestidge
Shahrad Rod Rassekh
Douglas G. Matsell
Publication date
01-06-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0401-1

Other articles of this Issue 3/2011

Clinical and Experimental Nephrology 3/2011 Go to the issue

Original Article

Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney

Original Article

Association between single nucleotide polymorphisms within genes encoding sirtuin families and diabetic nephropathy in Japanese subjects with type 2 diabetes

Original Article

Risk of macrovascular disease stratified by stage of chronic kidney disease in type 2 diabetic patients: critical level of the estimated glomerular filtration rate and the significance of hyperuricemia

Review Article

Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians

Original Article

Growth factor Midkine is involved in the pathogenesis of renal injury induced by protein overload containing endotoxin

Review Article

Treatment of metastatic renal cell carcinoma and renal pelvic cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits